Concerns over minimally invasive heart valve surgery

A new type of heart valve surgery known as transcatheter aortic valve implantation "cannot be justified on medical or cost effectiveness grounds" warn experts in a paper published in BMJ today.

Hans Van Brabandt from the Belgian Health Care Knowledge Centre and colleagues describe the procedure as "risky and costly" and call for better regulation and transparency around the use of such high risk medical devices.

TAVI is a minimally for patients with aortic who are too old or too ill for conventional . In patients who are suitable for conventional surgery, survival after TAVI is equivalent to conventional surgery, but the risk of stroke is higher. TAVI is also much more expensive than conventional surgery.

Since its introduction 10 years ago, around 40,000 procedures have been carried out worldwide.

TAVI is classed as a medical device. In Europe this means it needs only a simple quality certificate (CE mark) to gain access to the market, putting TAVI on the same footing as domestic appliances such as toasters. In contrast, the (FDA) demands trial evidence before it can license any innovative device. Thus TAVI was in use in Europe four years before the US.

However, guidance from the UK National Institute for Health and Clinical Excellence (NICE) says that the evidence for TAVI in patients who are suitable for is "inadequate."

The authors agree. After rigorous analysis of all the available data, combined with a study of real world TAVI practice in Europe, they conclude that "the arguments supporting the widespread use of TAVI do not stand up to scrutiny."

They also raise concerns about access to full trial data on TAVI and a lack of disclosure of financial interests among trial investigators.

They believe that Europe's regulatory system "should require high quality randomised trials to show clinical efficacy and safety before granting marketing approval to innovative, high risk medical devices."

They also call for a major improvement in transparency of information "to allow clinicians to practise evidence based medicine, patients to make informed decisions, and health technology assessment agencies to make the right judgements."

More information: Paper online: www.bmj.com/cgi/doi/10.1136/bmj.e4710

add to favorites email to friend print save as pdf

Related Stories

Results of the STACCATO Trial reported at TCT 2011

Nov 10, 2011

Researchers leading a clinical trial said that transapical transcatheter aortic valve implantation (a-TAVI) may be inferior to surgical aortic valve replacement (SAVR) in operable elderly patients. However results were only ...

Recommended for you

A prescription for better stroke care

28 minutes ago

Stroke patients are 70 per cent more likely to continue taking their stroke prevention medications one year later if they have a prescription in hand when discharged – according to researchers at St. Michael's ...

Vitamin D does not stop heart attack or stroke

Aug 26, 2014

(Medical Xpress)—Taking vitamin D tablets cannot ward off heart attacks or stroke according to a new study from researchers at the University of East Anglia (UEA) published in the American Journal of Cl ...

User comments